A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults)

Conclusions The results of this post hoc analysis of the persistence of PCV13 VE in adults ⩾65years, indicate that PCV13 was protective over the 5-year duration of the study, with no waning of efficacy observed. ClinicalTrials.gov identifier NCT00744263
Source: Trials in Vaccinology - Category: Infectious Diseases Source Type: research